Home › Funds › Acasta Partners UK LLP › VRDN
Acasta Partners UK LLP position in VRDN
VIRIDIAN THERAPEUTICS INC · Health Care
Acasta Partners UK LLP reported holding 5,000,000 shares of VRDN (VIRIDIAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$5.7M, representing 3.00% of its reported portfolio and ranking #7 among its reported holdings. Acasta Partners UK LLP first reported this position in Q3 2026.
Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR
How Acasta Partners UK LLP's VRDN position evolved
Acasta Partners UK LLP first disclosed a stake in VRDN in Q3 2026 at 5,000,000 shares (US$5.7M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 5.00M | $5.74M | New |
About VRDN and 13F data
VRDN (VIRIDIAN THERAPEUTICS INC) is a Health Care company. 37 other funds we track also report a position in VRDN — the largest reported positions include Bellevue Group AG (US$123.7M), Paradigm Biocapital Advisors LP (US$123.5M), Kynam Capital Management, LP (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VRDN
- Bellevue Group AG 6.73M sh · $123.67M · Q2 2026
- Paradigm Biocapital Advisors LP 6.72M sh · $123.52M · Q2 2026
- Kynam Capital Management, LP 6.45M sh · $118.56M · Q2 2026
- Fairmount Funds Management LLC 5.09M sh · $93.52M · Q2 2026
- Deep Track Capital, LP 3.59M sh · $66.00M · Q2 2026
- Venrock Adviser, LLC 3.26M sh · $59.85M · Q2 2026
- Avoro Capital Advisors LLC 2.50M sh · $45.92M · Q2 2026
- Context Capital Management, LLC 40.75M sh · $43.82M · Q2 2026
- BAKER BROS. ADVISORS LP 2.38M sh · $43.78M · Q2 2026
- Caligan Partners LP 2.19M sh · $40.30M · Q2 2026
- Novo Holdings A/S 2.13M sh · $39.22M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.79M sh · $32.93M · Q2 2026
More on Acasta Partners UK LLP
FAQ
How long has Acasta Partners UK LLP held VRDN?
Acasta Partners UK LLP has disclosed VRDN holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Acasta Partners UK LLP's current position in VRDN?
As of Q3 2026, Acasta Partners UK LLP holds 5.00M shares of VRDN (VIRIDIAN THERAPEUTICS INC), valued at $5.74M, representing 3.00% of its reported portfolio and ranking #7.
Has Acasta Partners UK LLP been buying or selling VRDN?
In the latest 13F filing (Q3 2026), Acasta Partners UK LLP newly opened its position in VRDN.
Which other funds hold VRDN?
Other major institutional holders of VRDN include Bellevue Group AG, Paradigm Biocapital Advisors LP, Kynam Capital Management, LP, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.